BioNova Announces FDA Fast Track Designation Granted to BN104 for the Treatment of Acute Leukemia
BioNova Pharmaceuticals Limited (BioNova) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to BN104 for the treatment of relapsed/refractory (R/R) acute leukemia.
